Skip to main content
Clinical Trials/CTRI/2023/02/049923
CTRI/2023/02/049923
Recruiting
未知

An observational study to evaluate the effectiveness and safety of Elidel® in infants and children affected by mild to moderate Atopic dermatitis (AD) in India

Mylan Pharmaceuticals Private Limited0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: L209- Atopic dermatitis, unspecified
Sponsor
Mylan Pharmaceuticals Private Limited
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Signed informed consent from patients’ parent(s) or legal guardian(s) in compliance with local regulation
  • 2\. Patients of Indian ethnicity
  • 3\. Male and female infants and children who are at least 3 months to a maximum of 5 years of age at baseline (V1\)
  • 4\. Diagnosis of mild to moderate Atopic dermatitis (SCORAD index \<50\)
  • 5\. Prescribed Elidel® 1% w/w for mild to moderate AD as part of routine clinical care and in accordance with product label prior to inclusion

Exclusion Criteria

  • 1\. Patients for whom Elidel® is not recommended according to the Package Insert
  • 2\. Patients with severe AD (SCORAD \=50\)
  • 3\. Active viral infections at the treatment site
  • 4\. Receiving systemic glucocorticoids, antibiotics, antifungals, immunomodulators, antihistamines and ultraviolet radiation therapy within the last 4 weeks before inclusion
  • 5\. Receiving any topical AD\-effective drugs within the last 2 weeks before inclusion
  • 6\. Known or suspected hypersensitivity to pimecrolimus or any component of the cream
  • 7\. Patients parent(s)/legal guardian (as applicable) that are not able to fulfill study requirements according to physician’s opinion
  • 8\. Patients parent(s) / legal guardian (as applicable) who refuse to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials